M. Guebre-Xabier

XBB.1.5 Spike Protein COVID-19 Vaccine Induces Broadly Neutralizing and Cellular Immune Responses Against EG.5.1 and Emerging XBB Variants

This study shows that a monovalent XBB.1.5 spike protein vaccine induces broader neutralizing antibodies and stronger cellular immunity against multiple SARS-CoV-2 variants compared to bivalent vaccines.

Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants

This study evaluates a nanoparticle vaccine against SARS-CoV-2 variants, showing it induces strong immune responses and protection in mice and baboons against multiple variants.

Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike and QuadrivalentSeasonal Influenza Hemagglutinin Nanoparticles with Matrix-M Adjuvant

This paper evaluates a combination vaccine against seasonal influenza and SARS-CoV-2 in animal models, showing it induces protective immune responses and prevents viral replication and disease.

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

This study shows that NVX-CoV2373 vaccine induces antibodies with both neutralizing and Fc-effector functions, which together provide maximal protection against SARS-CoV-2 in non-human primates.

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

This study evaluates the NVX-CoV2373 vaccine in cynomolgus macaques, showing it induces neutralizing antibodies and protects against SARS-CoV-2 infection in upper and lower airways.

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

This study evaluates the immunogenicity and protective efficacy of the NVX-CoV2373 SARS-CoV-2 vaccine in baboons and mice, showing strong immune responses and protection without enhanced disease.